Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
40
NAGE Quote, Financials, Valuation and Earnings
Last price:
$10.36
Seasonality move
:
-9.41%
Day range:
$10.85 - $11.51
52-week range:
$2.53 - $14.69
Dividend yield:
0%
P/E ratio:
67.73x
P/S ratio:
8.49x
P/B ratio:
16.37x
Volume:
1M
Avg. volume:
1M
1-year change:
274.59%
Market cap:
$905.9M
Revenue:
$99.6M
EPS (TTM):
$0.17
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Niagen Bioscience has 29.57% upside to fair value with a price target of -- per share.
NAGE vs. S&P 500
-
Over the past 5 trading days, Niagen Bioscience has underperformed the S&P 500 by -5.18% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Niagen Bioscience does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Niagen Bioscience has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Niagen Bioscience reported revenues of $30.5M.
Earnings Growth
-
Niagen Bioscience has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Niagen Bioscience reported earnings per share of $0.06.
Enterprise value:
850.4M
EV / Invested capital:
--
Price / LTM sales:
8.49x
EV / EBIT:
64.28x
EV / Revenue:
7.88x
PEG ratio (5yr expected):
--
EV / Free cash flow:
43.51x
Price / Operating cash flow:
46.88x
Enterprise value / EBITDA:
57.88x
Gross Profit (TTM):
$67.5M
Return On Assets:
22.44%
Net Income Margin (TTM):
13.07%
Return On Equity:
36.08%
Return On Invested Capital:
36.08%
Operating Margin:
15.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $77.3M | $83.2M | $107.9M | $22.2M | $30.5M | |
| Gross Profit | $45.8M | $50.7M | $67.5M | $13.5M | $19.3M | |
| Operating Income | -$12.9M | -$4.4M | $13.2M | -$731K | $4.8M | |
| EBITDA | -$11.1M | -$2.7M | $14.7M | -$341K | $5.1M | |
| Diluted EPS | -$0.15 | -$0.05 | $0.17 | -$0.01 | $0.06 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $63.2M | $44.5M | $46.6M | $49M | $76.2M | |
| Total Assets | $69M | $52.9M | $53.8M | $54.1M | $81.3M | |
| Current Liabilities | $19.8M | $18.7M | $18.4M | $19.5M | $20.8M | |
| Total Liabilities | $25.2M | $27.1M | $25.8M | $25.1M | $26M | |
| Total Equity | $43.8M | $25.9M | $28M | $29M | $55.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.1M | $4.6M | $19.7M | $295K | $7.9M | |
| Cash From Investing | -$400K | -$93K | -$134K | -$41K | -$32K | |
| Cash From Financing | $7.7M | -$103K | $8.5M | -$14K | $3.1M | |
| Free Cash Flow | -$5.5M | $4.5M | $19.5M | $254K | $7.9M | |
NAGE
Sector
Market Cap
$905.9M
$34.4M
Price % of 52-Week High
78.29%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
274.59%
-37.36%
Beta (5-Year)
2.137
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$11.68
200-day SMA
Buy
Level
$7.41
Bollinger Bands (100)
Buy
Level
6.55 - 12.13
Chaikin Money Flow
Sell
Level
-1.9M
20-day SMA
Sell
Level
$12.81
Relative Strength Index (RSI14)
Sell
Level
42.44
ADX Line
Sell
Level
37.94
Williams %R
Buy
Level
-83.0729
50-day SMA
Sell
Level
$11.77
MACD (12, 26)
Buy
Level
3.12
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-3.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.0088)
Buy
CA Score
(Annual)
Level (1.2171)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-2.2492)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Stock Forecast FAQ
In the current month, NAGE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NAGE average analyst price target in the past 3 months is --.
-
Where Will Niagen Bioscience Stock Be In 1 Year?
According to analysts, the consensus estimate is that Niagen Bioscience share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Niagen Bioscience?
Analysts are divided on their view about Niagen Bioscience share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Niagen Bioscience is a Sell and believe this share price will drop from its current level to --.
-
What Is Niagen Bioscience's Price Target?
The price target for Niagen Bioscience over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NAGE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Niagen Bioscience is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NAGE?
You can purchase shares of Niagen Bioscience via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Niagen Bioscience shares.
-
What Is The Niagen Bioscience Share Price Today?
Niagen Bioscience was last trading at $10.36 per share. This represents the most recent stock quote for Niagen Bioscience. Yesterday, Niagen Bioscience closed at $11.50 per share.
-
How To Buy Niagen Bioscience Stock Online?
In order to purchase Niagen Bioscience stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
